The effectiveness of Vonoprazan for delayed bleeding after ESD in antithrombotic drug-users: a prospective study.

The effectiveness of Vonoprazan for delayed bleeding after ESD in antithrombotic drug-users: a prospective study. - The effectiveness of Vonoprazan for delayed bleeding after ESD in antithrombotic drug-users: a prospective study.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029300

Enrollment

Registered

2017-10-01

Start date

2017-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

early gastric cancer, gastric adenoma

Interventions

prescription of vonoprazan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)antithrombotic drug-users 2)criteria and expanded criteria for gastric ESD 3)withdrawal antithrombotic drug in accordance with the guidelines-Japan Gastroenterological Endoscopy Society

Exclusion criteria

Exclusion criteria: 1)perforation during ESD 2)allergy for vonoprazan

Design outcomes

Primary

Measure	Time frame
the rate of delayed bleeding after ESD	—

Secondary

Measure	Time frame
the rate of thromboembolism, bleeding event which are not assosiated with ESD(cerebral hemorrhage, gastrointestinal bleeding), the need for blood transfusion,the days of hospitalization, mortality	—

Countries

Japan

Contacts

Public Contacthiroshi takayama

kurashiki central hospital gastroenterology

ht14835@kchnet.or.jp086-422-0210

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026